Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease.
Establishment of Helicobacter pylori infection as an etiologic agent of peptic ulcer disease and other gastric pathologies marked a revolution in gastroenterology which spurred an enormous interest in gastric physiology and immunology research. The association was soon also demonstrated in children...
| Publicado en: | Pediatric Research |
|---|---|
| Autores principales: | , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Oct 04, 2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119311106&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 119311106 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00313998 4FF jtl: Pediatric Research issn: 00313998 maglogo: N pubinfo: dt: Oct 04, 2016 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 119311106 119311106 NLM27701380 119311106 10.1038/pr.2016.199 NLM27701380 119311106 ppct: 1 formats: tig: atl: Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease. aug: au: Blanchard, Thomas G Czinn, Steven J affil: Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, U.S.A sug: subj: Helicobacter Pylori Peptic Ulcer Prevention and Control Bacterial Vaccines Therapeutic Use Helicobacter Infections Prevention and Control Gastritis Prevention and Control Child Prevalence Mice Biological Response Modifiers Clinical Trials Immunization Adolescence Stomach Neoplasms Prevention and Control Toxins Animals Escherichia Coli Immunology Duodenal Ulcer Prevention and Control Child: 6-12 years Adolescent: 13-18 years ab: Establishment of Helicobacter pylori infection as an etiologic agent of peptic ulcer disease and other gastric pathologies marked a revolution in gastroenterology which spurred an enormous interest in gastric physiology and immunology research. The association was soon also demonstrated in children as well. Application of antimicrobial therapies have proven remarkably efficacious in eradicating H. pylori and curing pediatric patients of duodenal ulcers as well as gastritis, negating a lifetime of ineffective therapy and life-threatening disease. Countries with high H. pylori prevalence and where H. pylori associated gastric cancer remains a primary cause of death due to cancer however would benefit from childhood vaccination. Studies in rodents and humans utilizing oral vaccination with bacterial exotoxin adjuvants demonstrated potential for limiting H. pylori colonization in the stomach. Almost 25 y of vaccine research recently culminated in a phase III clinical trial of over 4,000 children aged 6-15 y old to test an oral vaccine consisting of the H. pylori urease B subunit genetically fused to the E. coli heat labile toxin. Vaccination was demonstrated to have an efficacy of over 70%. Vaccination may now serve as an effective strategy to significantly reduce H. pylori associated disease in children throughout the world. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|